F. Hoffmann-La Roche AG
Switzerland
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Roche retains sole responsibility for content © 2018 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.
1 August 2018 - 31 July 2019
Region: Global
Subject/journal group: All
The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 August 2018 - 31 July 2019 which are tracked by the Nature Index.
Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
| AC | FC |
|---|---|
| 141 | 49.95 |
Outputs by subject (FC)
| Subject | AC | FC | |
|---|---|---|---|
| Life Sciences | 120 | 40.37 | |
| Cancer Cell | 4 | 1.40 | |
| Cancer Research | 4 | 1.49 | |
| Cell | 4 | 1.96 | |
| Cell Stem Cell | 1 | 0 | |
| Developmental Cell | 1 | 0.07 | |
| Genome Research | 3 | 0.21 | |
| Immunity | 3 | 1.67 | |
| Journal of Biological Chemistry | 8 | 3.70 | |
| Journal of Clinical Investigation | 2 | 0.14 | |
| Journal of Experimental Medicine | 7 | 1.56 | |
| Journal of Neuroscience | 4 | 2.93 | |
| Molecular Cell | 2 | 1.04 | |
| Nature | 7 | 2.05 | |
| Nature Cell Biology | 2 | 0.21 | |
| Nature Communications | 17 | 3.42 | |
| Nature Genetics | 2 | 0.03 | |
| Nature Immunology | 5 | 0.73 | |
| Nature Medicine | 6 | 1.72 | |
| Nature Neuroscience | 1 | 0.21 | |
| Nature Structural & Molecular Biology | 1 | 0.03 | |
| Neuron | 2 | 0.90 | |
| PLOS Biology | 1 | 0.05 | |
| PLOS Genetics | 3 | 1.16 | |
| Proceedings of the National Academy of Sciences of the United States of America | 11 | 4.74 | |
| Science | 1 | 0.57 | |
| Science Advances | 1 | 0 | |
| Science Translational Medicine | 9 | 4.66 | |
| The EMBO Journal | 1 | 0.11 | |
| eLife | 7 | 3.62 | |
| Chemistry | 24 | 10.09 | |
| Physical Sciences | 6 | 0.97 | |
Highlight of the month
Some myelin-making cells missing in multiple sclerosis
© ROGER HARRIS/SCIENCE PHOTO LIBRARY/Getty
The brains of people with multiple sclerosis have different kinds of oligodendrocyte cells than people without the disease, even in brain regions not thought affected by the chronic inflammatory disorder.
The study — one of the first to use single-cell RNA sequencing to interrogate a neurological disease — could help explain how multiple sclerosis progresses and how to improve treatment strategies.
Oligodendrocytes help wrap nerve fibres in the protective myelin sheath that is lost in multiple sclerosis.
Starting with single oligodendrocytes from the white matter of healthy brains, a research team that included scientists from Roche identified many subpopulations of these myelin-making cells. In brains from multiple sclerosis-affected patients, however, certain subpopulations were missing or altered, both within disease lesions and in normal-appearing tissue.
The findings could help explain why the restoration of damaged myelin is impaired in multiple sclerosis.
- Nature 566, 543–547 (2019). doi: 10.1038/s41586-019-0903-2
See more research highlights from F. Hoffmann-La Roche AG
More research highlights from F. Hoffmann-La Roche AG
Top articles by Altmetric score in current window
Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergy
Nature Medicine
2019-06-24
Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Nature Medicine
2018-11-26
1 August 2018 - 31 July 2019
International vs. domestic collaboration by FC
- 8.09% Domestic
- 91.91% International
Note: Hover over the graph to view the percentage of collaboration.
Top 10 domestic collaborators by FC (19 total)
- F. Hoffmann-La Roche AG, Switzerland
- Domestic institution
-
University of Basel (UB), Switzerland
(5.46)
-
Department of Biomedicine Basel, Switzerland
(2.86)
-
University of Zurich (UZH), Switzerland
(2.44)
-
University Children's Hospital Basel (UKBB), Switzerland
(2.17)
-
Paul Scherrer Institute (PSI), Switzerland
(1.24)
-
Swiss Federal Institute of Technology Zurich (ETH Zurich), Switzerland
(1.12)
-
Novartis International AG, Switzerland
(0.42)
-
Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland
(0.37)
-
Therachon AG, Switzerland
(0.37)
-
EPFL Interfaculty Institute of Bioengineering (IBI), Switzerland
(0.34)
Top 10 international collaborators by FC (635 total)
- F. Hoffmann-La Roche AG, Switzerland
- Foreign institution
-
Stanford University, United States of America (USA)
(5.96)
-
Harvard University, United States of America (USA)
(5.15)
-
University of California, San Francisco (UCSF), United States of America (USA)
(3.86)
-
The University of Texas MD Anderson Cancer Center, United States of America (USA)
(3.03)
-
Leibniz Association, Germany
(2.24)
-
National Institute for Health and Medical Research (INSERM), France
(2.17)
-
The University of Texas at Austin (UT Austin), United States of America (USA)
(2)
-
California Institute of Technology (Caltech), United States of America (USA)
(2)
-
University of Colorado Boulder (CU-Boulder), United States of America (USA)
(1.91)
-
University College London (UCL), United Kingdom (UK)
(1.79)
Note: Collaboration is determined by the fractional count (FC), which is listed in parentheses.
Affiliated joint institutions and consortia
Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
